Meta description: A multicenter trial evaluates the use of digital three dimensional simulation to guide transcatheter aortic valve replacement in aortic regurgitation, aiming to inform clinical and regulatory decisions.
On February 11 2026 the study is enrolling by invitation across a network of centers in China including Xijing Hospital; Fu Wai Hospital; West China Hospital; Beijing Anzhen Hospital; General Hospital of Ningxia Medical University; Chinese Academy of Medical Sciences Fuwai Hospital; People’s Hospital of Xinjiang Uygur Autonomous Region; Henan Provincial Chest Hospital; Union Hospital Tongji Medical College Huazhong University of Science and Technology; Fujian Medical University Union Hospital; Guangdong Provincial People’s Hospital; Xinqiao Hospital of Chongqing; The Affiliated Hospital of Qingdao University; First Affiliated Hospital Xi’an Jiaotong University; Yan’an Hospital of Kunming City; Dong’e People’s Hospital. The approach relies on a digital three dimensional simulation technique described as the device component in the trial listing. The public registry is ClinicalTrials.gov under NCT07398911.
What changed with digital three dimensional simulation guided TAVR
The study introduces a planning and guidance method that uses a digital three dimensional simulation to assist transcatheter aortic valve replacement in patients with aortic regurgitation. Enrollment by invitation and the spread across multiple centers indicate a coordinated effort to assess feasibility and safety in a real world clinical context. The source text notes that the intervention is described as Device: 3D simulation technique, highlighting the modeling aspect as a central element of the study. This line reflects a regulatory style description that makes explicit the intended use of the modeling approach as part of a device oriented trial.
Why this matters for patients and clinicians
Digital three dimensional simulation can support planning and decision making for complex valve procedures. While the study is not yet a marketed device, its design aligns with how investigators in regulatory ecosystems describe investigational tools and their intended purpose. Stakeholders including patients, surgeons, and regulatory teams can watch for updates on safety, feasibility, and projected performance based on transparent registries and registry like reporting.
Who is affected
The AR population targeted by this trial includes adults with aortic regurgitation who may be considered for transcatheter valve intervention. Enrollment by invitation suggests that participation is limited to selected centers and eligible patients at these sites. The multi center sponsor list signals a collaborative effort across major hospitals in China to evaluate how digital simulation tools may influence planning, workflow, and outcomes in real world settings. The clinical trial listing provides a public reference for researchers and clinicians seeking more information.
Evidence and regulatory context
Regulatory style reporting for this trial emphasizes transparency about intended use and scope of the digital modeling approach. The trial is listed on ClinicalTrials.gov under NCT07398911 and involves the following sponsors: Xijing Hospital; Fu Wai Hospital; West China Hospital; Beijing Anzhen Hospital; General Hospital of Ningxia Medical University; Chinese Academy of Medical Sciences Fuwai Hospital; People’s Hospital of Xinjiang Uygur Autonomous Region; Henan Provincial Chest Hospital; Union Hospital Tongji Medical College Huazhong University of Science and Technology; Fujian Medical University Union Hospital; Guangdong Provincial People’s Hospital; Xinqiao Hospital of Chongqing; The Affiliated Hospital of Qingdao University; First Affiliated Hospital Xi an Jiaotong University; Yan an Hospital of Kunming City; and Dong e People’s Hospital. The registration signals a formal research effort rather than a marketed device. Readers should consult the listing for full details and updates, including study design and enrollment status. External linkage to the registry is provided in the article.
For clinicians and regulators, this context supports tracking the evolution of digital planning tools as potential adjuncts to interventional procedures. It also underscores the importance of clearly defined intended use statements for investigational technology in line with MDR oriented documentation.
Safety and performance considerations
Because the trial is enrolling and no results are presented in the source text, there are no performance or safety findings to report. Stakeholders should expect ongoing evaluation of feasibility, patient selection criteria, procedural planning accuracy, and potential impact on outcomes once data become available. As with any investigational approach, the trial will require rigorous monitoring, predefined safety endpoints, and transparent reporting through appropriate channels. The description Device: 3D simulation technique is presented as part of the study protocol rather than a marketed solution, aligning with regulatory expectations for investigational devices.
Implementation and workflow
If digital three dimensional simulation proves feasible, centers may integrate advanced modeling into preoperative planning workflows for transcatheter valve strategies in aortic regurgitation. The invitation based enrollment signals selective participation and emphasizes coordination among centers. Practitioners can monitor the ClinicalTrials.gov registry and the study sponsor communications for updates on protocol changes, inclusion criteria, and potential expansion to additional sites.
What to watch next
Key questions include whether the digital simulation improves planning accuracy or shortens procedure times in this patient group. Regulators will look for clear documentation of intended use, safety monitoring, and outcome reporting. The multi center nature of the trial suggests that results may inform future device development, regulatory submissions, and clinical guidelines related to imaging driven planning for transcatheter interventions.
FAQ
- What is being studied? The study assesses digital three dimensional simulation guided transcatheter aortic valve replacement for aortic regurgitation.
- Where are centers located? Centers across China are participating, including a number of major hospitals listed in the registry.
- How can patients participate? Enrollment is by invitation through the listed centers.
- Where can I read more? The public registry is available at the listed ClinicalTrials.gov page.
- What does this mean for regulation? The trial demonstrates how investigators describe investigational tools and intended use in regulatory style documentation.
In summary a multicenter trial explores digital three dimensional simulation to guide transcatheter valve replacement in aortic regurgitation. The study highlights the regulatory driven description of intended use and will illuminate feasibility and safety as data mature. Clinicians and regulators should track updates via the ClinicalTrials.gov listing and sponsor communications.
Disclaimer: This article provides information for professional readers and is not legal advice. It summarizes publicly available trial materials and does not constitute regulatory guidance.
https://clinicaltrials.gov/study/NCT07398911?term=medical+device